Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CNTA
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | Buy | TD Cowen | |
9/20/2024 | $11.00 → $26.00 | Equal-Weight → Overweight | Morgan Stanley |
9/19/2024 | $33.00 | Buy | B. Riley Securities |
7/18/2024 | $14.00 | Outperform | Oppenheimer |
11/15/2023 | $4.00 → $11.00 | Hold → Buy | Jefferies |
10/26/2023 | $4.00 → $8.00 | Underweight → Equal-Weight | Morgan Stanley |
6/21/2023 | Outperform | Evercore ISI | |
6/12/2023 | $9.00 | Buy | Guggenheim |
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025Fireside Chat: 1:00 PM ET Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: February 12, 2025Fireside Chat: 10:40 AM ET Event: TD Cowen 45th Annual Health Care ConferenceDate: March 4, 2025Fireside Chat: 1:50 PM ET Event: Leerink Partners Global Healthcare ConferenceDate: March 11,
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD
TD Cowen initiated coverage on Centessa Pharmaceuticals
TD Cowen initiated coverage of Centessa Pharmaceuticals with a rating of Buy
Centessa Pharmaceuticals upgraded by Morgan Stanley with a new price target
Morgan Stanley upgraded Centessa Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $26.00 from $11.00 previously
B. Riley Securities initiated coverage on Centessa Pharmaceuticals with a new price target
B. Riley Securities initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Chief Business Officer Weinhoff Gregory M sold $175,270 worth of Ordinary Shares (11,494 units at $15.25), decreasing direct ownership by 8% to 134,021 units (SEC Form 4)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
Chief Executive Officer Saha Saurabh sold $876,088 worth of Ordinary Shares (55,000 units at $15.93), decreasing direct ownership by 14% to 331,017 units (SEC Form 4)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
General Counsel Hussain Iqbal J exercised 6,000 units of Ordinary Shares at a strike of $5.84 and sold $97,065 worth of Ordinary Shares (6,000 units at $16.18) (SEC Form 4)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
SEC Form 144 filed by Centessa Pharmaceuticals plc
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
SEC Form 8-K filed by Centessa Pharmaceuticals plc
8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)
Amendment: SEC Form 10-Q/A filed by Centessa Pharmaceuticals plc
10-Q/A - Centessa Pharmaceuticals plc (0001847903) (Filer)
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)